Only 5 Companies in This Track Have Reached Series C Funding to Date Despite 21.8 Billion Yuan Investment

China's synthetic biology sector has attracted 21.8 billion yuan across 301 financing events since 2015, yet the market remains heavily concentrated in early-stage development with only five companies reaching Series C or beyond. While global market projections suggest the sector could reach $95 billion by 2034, domestic investment has shifted from a 2022 peak toward a more diversified distribution across platform tools, biobased materials, and alternative proteins. This maturation process highlights a critical transition for the sector as startups face increasing pressure to move beyond research and development into large-scale commercial verification.

The Chinese synthetic biology sector has recorded 301 financing events involving 110 companies since 2015, totaling 21.8 billion yuan in investment. Despite this capital influx, the industry faces a significant bottleneck in scaling, with only five companies—including Junhemeng, Yikele Biology, and Meisai Biology—reaching Series C or above. The vast majority of the market remains in the early stages of development, with 70% of companies yet to pass Series B. Financing is overwhelmingly localized, with 97% of deals denominated in RMB and minimal participation from overseas US-dollar funds, reflecting a highly domestic capital structure.

Platform and tool-based companies have emerged as the primary capital magnets, securing 45% of total industry funding. Major players like Weiyuan Synthetic, Taitron Biotech, and Ketaia Biotech operate as biological contract manufacturers or cell factory designers, theoretically capable of replicating technologies across pharmaceuticals, food, and materials. However, this multi-application approach faces commercialization hurdles due to varying regulatory and process requirements across different sectors. For example, Taitron Biotech secured a 2.1 billion yuan Series A+ round in 2022, but its financing pace has since slowed as the market evaluates the long-term viability of the platform-type business model.

The biobased materials and food sectors show contrasting investment patterns. Biobased materials, particularly polyhydroxyalkanoates (PHA), are highly concentrated, with Bluepha, Weigou Workshop, and Lifu Biotech accounting for 72% of the category's funding. While the logic of replacing petroleum-based plastics is clear, high production costs and long commercialization cycles have tempered recent investment, with Bluepha not disclosing new rounds since early 2023. Conversely, the food and alternative protein sector saw explosive growth in 2025, with 17 financing events focused on human milk oligosaccharides (HMOs), ergothioneine, and microbial proteins. Hongmu Biotech became a standout in this space as the first domestic HMO raw material enterprise to pass safety assessments from the Ministry of Agriculture and Rural Affairs.

Recent data from 2025 and the first half of 2026 indicates a shifting market structure where capital is becoming more selective. While 2022 marked a peak for speculative investment in platform companies, 2025 saw a more even distribution of funds across specific application directions. The first half of 2026 reported 3.44 billion yuan in financing across 29 events, though this figure is heavily skewed by Weiyuan Synthetic’s massive 1.5 billion yuan Series B round. Excluding this single deal, the growth in the sector remains modest, suggesting that investors are now prioritizing companies that can demonstrate clear paths to regulatory compliance and commercial scale-up.